Milsaperidone (VHX-896) vs Perseris

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Milsaperidone (VHX-896)

Marketed by Vanda Pharmaceuticals

Approved in Schizophreniasmall molecule
Weak signal

NCT06494397 · Phase 1 · completed

Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.

No aligned efficacy figure on record for this race.

Perseris

Rights held by Indivior Pharmaceuticals, Inc.; US product discontinued

Approved in Schizophreniasmall molecule
Reliable signal

NCT02109562 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial with 354 participants and a clinical primary endpoint measuring change in PANSS total score. The primary endpoint was met for both RBP-7000 doses: PANSS scores improved significantly more than with placebo.

Reported efficacy

Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score (Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation): Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score (Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation): RBP-7000 90 mg -15.367 units on a scale (Standard Error 1.223) | RBP-7000 120 mg -16.456 units on a scale (Standard Error 1.2073) vs Placebo -9.219 units on a scale (Standard Error 1.2162) (met)

Result source: NCT02109562

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMilsaperidone (VHX-896)Perseris
PANSS total, change—Not reported-16.5 vs -9.2−7.2 vs placebo120 mg · wk 8 · n 114NCT02109562
7 other results
  • -15.4 vs -9.2 90 mg · wk 8 · n 111 · Phase 3 · primary NCT02109562
  • -1.2 vs -8.2 wk 24.14 · n 408 · Phase 3 · secondary NCT02203838
  • -1.2 vs -4.8 wk 4.14 · n 408 · Phase 3 · secondary NCT02203838
  • -9.4 vs -8.2 120 mg · wk 24.14 · n 33 · Phase 3 · secondary NCT02203838
  • -2.4 vs -4.8 120 mg · wk 4.14 · n 33 · Phase 3 · secondary NCT02203838
  • -10 vs -8.2 90 mg · wk 24.14 · n 31 · Phase 3 · secondary NCT02203838
  • -8.3 vs -4.8 90 mg · wk 4.14 · n 31 · Phase 3 · secondary NCT02203838
CGI-S, change—Not reported-0.1 vs -0.3+0.2 vs placebowk 24.14 · n 408NCT02203838
7 other results
  • 0 vs -0.3 wk 4.14 · n 408 · Phase 3 · secondary NCT02203838
  • -0.9 vs -0.5 120 mg · wk 8 · n 114 · Phase 3 · secondary NCT02109562
  • -0.9 vs -0.5 90 mg · wk 8 · n 111 · Phase 3 · secondary NCT02109562
  • -0.4 vs -0.3 120 mg · wk 24.14 · n 33 · Phase 3 · secondary NCT02203838
  • -0.1 vs -0.3 120 mg · wk 4.14 · n 33 · Phase 3 · secondary NCT02203838
  • -0.3 vs -0.3 90 mg · wk 24.14 · n 31 · Phase 3 · secondary NCT02203838
  • -0.2 vs -0.3 90 mg · wk 4.14 · n 31 · Phase 3 · secondary NCT02203838
PANSS response—Not reported—Not reported
PSP, change—Not reported—Not reported
Relapse (% of patients)—Not reported—Not reported

PANSS total, change

Milsaperidone (VHX-896)
—Not reported
Perseris
-16.5 vs -9.2−7.2 vs placebo120 mg · wk 8 · n 114NCT02109562
7 other results
  • -15.4 vs -9.2 90 mg · wk 8 · n 111 · Phase 3 · primary NCT02109562
  • -1.2 vs -8.2 wk 24.14 · n 408 · Phase 3 · secondary NCT02203838
  • -1.2 vs -4.8 wk 4.14 · n 408 · Phase 3 · secondary NCT02203838
  • -9.4 vs -8.2 120 mg · wk 24.14 · n 33 · Phase 3 · secondary NCT02203838
  • -2.4 vs -4.8 120 mg · wk 4.14 · n 33 · Phase 3 · secondary NCT02203838
  • -10 vs -8.2 90 mg · wk 24.14 · n 31 · Phase 3 · secondary NCT02203838
  • -8.3 vs -4.8 90 mg · wk 4.14 · n 31 · Phase 3 · secondary NCT02203838

CGI-S, change

Milsaperidone (VHX-896)
—Not reported
Perseris
-0.1 vs -0.3+0.2 vs placebowk 24.14 · n 408NCT02203838
7 other results
  • 0 vs -0.3 wk 4.14 · n 408 · Phase 3 · secondary NCT02203838
  • -0.9 vs -0.5 120 mg · wk 8 · n 114 · Phase 3 · secondary NCT02109562
  • -0.9 vs -0.5 90 mg · wk 8 · n 111 · Phase 3 · secondary NCT02109562
  • -0.4 vs -0.3 120 mg · wk 24.14 · n 33 · Phase 3 · secondary NCT02203838
  • -0.1 vs -0.3 120 mg · wk 4.14 · n 33 · Phase 3 · secondary NCT02203838
  • -0.3 vs -0.3 90 mg · wk 24.14 · n 31 · Phase 3 · secondary NCT02203838
  • -0.2 vs -0.3 90 mg · wk 4.14 · n 31 · Phase 3 · secondary NCT02203838

PANSS response

Milsaperidone (VHX-896)
—Not reported
Perseris
—Not reported

PSP, change

Milsaperidone (VHX-896)
—Not reported
Perseris
—Not reported

Relapse (% of patients)

Milsaperidone (VHX-896)
—Not reported
Perseris
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Milsaperidone (VHX-896): 0 of 4 rows · Perseris: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPerseris
Dropout rate
28.6%120 mga
NCT02109562 · Phase 3 · combination
show 8 more results
22.4%90 mg
NCT02109562 · Phase 3 · combination
54.5%120 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
51.6%90 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
51.5%De Novo Participants
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
78.3%180 mg subcutaneous
NCT03978832 · Phase 4 · registry result, not featured evidence
40%120 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
6.7%90 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
6.7%60 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
1.7%120 mga
NCT02109562 · Phase 3 · combination
show 8 more results
0%90 mg
NCT02109562 · Phase 3 · combination
6.1%120 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
9.7%90 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
11.3%De Novo Participants
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
1.4%180 mg subcutaneous
NCT03978832 · Phase 4 · registry result, not featured evidence
—120 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
—90 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
Serious AEs
0.9%120 mga
NCT02109562 · Phase 3 · combination
show 8 more results
0%90 mg
NCT02109562 · Phase 3 · combination
9.1%120 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
9.7%90 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
6.1%De Novo Participants
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
4.3%180 mg subcutaneous
NCT03978832 · Phase 4 · registry result, not featured evidence
6.7%120 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
0%90 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
0%60 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
120 mga
injection site pain 22.2% (placebo 19.5%)
headache 15.4% (placebo 23.7%)
weight increased 12.8% (placebo 3.4%)
NCT02109562 · Phase 3 · combination
show 8 more results
90 mg
headache 17.4% (placebo 23.7%)
injection site pain 15.7% (placebo 19.5%)
weight increased 13% (placebo 3.4%)
NCT02109562 · Phase 3 · combination
120 mg
injection site pain 21.2% (placebo 7.1%)
injection site induration 9.1% (placebo 0%)
injection site nodule 9.1% (placebo 3.6%)
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
90 mg
headache 12.9% (placebo 0%)
injection site pain 12.9% (placebo 7.1%)
insomnia 12.9% (placebo 3.6%)
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
weight increased 14.7% (placebo 3.6%)
injection site pain 12.7% (placebo 7.1%)
injection site nodule 7.1% (placebo 3.6%)
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
180 mg subcutaneous
upper respiratory tract infection 13%
blood prolactin increased 8.7%
decreased appetite 8.7%
NCT03978832 · Phase 4 · registry result, not featured evidence
120 mg
cough 20%
dyspepsia 20%
weight increased 20%
NCT01677377 · Phase 2 · registry result, not featured evidence
90 mg
weight increased 33.3%
headache 20%
dyspepsia 13.3%
NCT01677377 · Phase 2 · registry result, not featured evidence
60 mg
weight increased 26.7%
headache 20%
rash 20%
NCT01677377 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 6 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Perseris

PANSS Total -16.456 vs -9.219 placebo score @ 8wk120 mg
absolute change · score
NCT02109562 · Phase 3 · combination
show 7 more results
-2.4 vs -4.8 placebo score @ 4.14wk120 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-9.4 vs -8.2 placebo score @ 24.14wk120 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-15.367 vs -9.219 placebo score @ 8wk90 mg
NCT02109562 · Phase 3 · combination
-8.3 vs -4.8 placebo score @ 4.14wk90 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-10 vs -8.2 placebo score @ 24.14wk90 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-1.2 vs -4.8 placebo score @ 4.14wk
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-1.2 vs -8.2 placebo score @ 24.14wk
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-S -0.914 vs -0.518 placebo score @ 8wk120 mg
absolute change · score
NCT02109562 · Phase 3 · combination
show 7 more results
-0.1 vs -0.3 placebo score @ 4.14wk120 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.4 vs -0.3 placebo score @ 24.14wk120 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.868 vs -0.518 placebo score @ 8wk90 mg
NCT02109562 · Phase 3 · combination
-0.2 vs -0.3 placebo score @ 4.14wk90 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.3 vs -0.3 placebo score @ 24.14wk90 mg
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
0 vs -0.3 placebo score @ 4.14wk
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.1 vs -0.3 placebo score @ 24.14wk
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
PANSS Total -10.9 vs -20.2 placebo score @ 52wk120 mg
absolute change · score
End of Study
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-12.5 vs -20.2 placebo score @ 52wk90 mg
End of Study
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.4 vs -20.2 placebo score @ 52wk
End of Study
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-S -0.3 vs -1 placebo score @ 52wk120 mg
absolute change · score
End of Study
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-0.5 vs -1 placebo score @ 52wk90 mg
End of Study
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
-0.2 vs -1 placebo score @ 52wk
End of Study
NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3
PANSS Total -0.2 score @ 0wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 2
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total 0.9 score @ 1wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 8
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total 0.7 score @ 2wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 15
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.4 score @ 3wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 22
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.9 score @ 4wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 2 Day 29
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.5 score @ 7wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 2 Day 50
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -2.9 score @ 8wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 3 Day 57
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.9 score @ 12wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 4 Day 85
NCT03978832 · Phase 4 · registry result, not featured evidence

+ 10 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Perseris's landscape